pI: 9.7601 |
Length (AA): 677 |
MW (Da): 80923 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 14 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
2 | 264 | 1ihg (A) | 13 | 235 | 26.00 | 0 | 1 | 0.49 | 0.32 |
4 | 219 | 2bit (X) | 3 | 165 | 29.00 | 0 | 1 | 0.38 | -0.13 |
2 | 218 | 1qng (A) | 2 | 171 | 32.00 | 0 | 1 | 0.422032 | 0.12 |
2 | 218 | 1a58 (A) | 4 | 176 | 28.00 | 0.00026 | 1 | 0.430732 | 0.13 |
3 | 218 | 2wfi (A) | 6 | 177 | 29.00 | 0 | 1 | 0.418555 | -0.06 |
3 | 225 | 2ose (A) | 13 | 213 | 25.00 | 0.00019 | 1 | 0.262894 | 0.3 |
6 | 219 | 3ici (A) | 13 | 174 | 31.00 | 0 | 1 | 0.3636 | 0.06 |
7 | 218 | 1z81 (A) | 43 | 210 | 31.00 | 0.0045 | 1 | 0.414346 | 0.02 |
17 | 231 | 1zkc (A) | 287 | 447 | 23.00 | 0.00000038 | 1 | 0.169078 | 0.82 |
490 | 671 | 4uos (A) | 1 | 183 | 10.00 | 0.29 | 0 | 0.464833 | -1.31 |
1 | 218 | 2igv (A) | 1 | 171 | 29.00 | 0.000076 | 1 | 0.393585 | 0.4 |
2 | 218 | 1a58 (A) | 4 | 176 | 28.00 | 0.00032 | 1 | 0.437106 | 0.05 |
3 | 218 | 1qng (A) | 3 | 171 | 33.00 | 0.0000021 | 1 | 0.453627 | 0.17 |
489 | 670 | 4uos (A) | 1 | 183 | 10.00 | 0.55 | 0 | 0.468031 | -1.31 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs, Oocyst. | Otto TD Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 24 hs, early schizont, late ring, Ring, Sporozoite, Female Gametocyte, Male Gametocyte. | Otto TD PlasmoDB Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | intra-erythrocytic - 32 hs, merozoite, sporozoite, early ring, early trophozoite, late trophozoite. | Otto TD PlasmoDB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, gametocyte. | Otto TD PlasmoDB |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Ortholog group members (OG5_139999)
Species | Accession | Gene Product |
---|---|---|
Babesia bovis | BBOV_IV006890 | peptidyl-prolyl cis-trans isomerase, putative |
Caenorhabditis elegans | CELE_T27D1.1 | Protein CYN-9 |
Neospora caninum | NCLIV_030640 | peptidyl-prolyl cis-trans isomerase, cyclophylin protein, putative |
Plasmodium berghei | PBANKA_1227200 | peptidyl-prolyl cis-trans isomerase, putative |
Plasmodium falciparum | PF3D7_0803000 | peptidyl-prolyl cis-trans isomerase |
Plasmodium knowlesi | PKNH_0115900 | peptidyl-prolyl cis-trans isomerase, putative |
Plasmodium vivax | PVX_093595 | peptidyl-prolyl cis-trans isomerase, putative |
Plasmodium yoelii | PY05631 | Drosophila melanogaster CG12343 gene product, putative |
Toxoplasma gondii | TGME49_229940 | cyclophilin, putative |
Theileria parva | TP03_0222 | peptidyl-prolyl cis-trans isomerase, putative |
Theileria parva | TP03_0221 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_536100 | ubiquitin-protein ligase bre-1, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
TGME49_229940 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_229940 | Toxoplasma gondii | Probably essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Rattus norvegicus | Cyclophilin A | 164 aa | 23.6% | 212 aa | Compounds | References |